OTC pediculicide drug products final monograph
This article was originally published in The Tan Sheet
Amended to clarify that labeling for OTC lice treatments containing active ingredient pyrethrum extract should "provide a specified concentration range of pyrethrins in a formulated product," FDA announces in the Aug. 13 Federal Register. The final monograph is revised to read: "The active ingredients of the product consist of the combination of pyrethrum extract (providing a concentration of pyrethrins of .17% to .33%) with piperonyl butoxide (2% to 4%) in a non-aerosol dosage formulation." Previously, the monograph had said "pyrethrum extract (.17% to .33%)." The change was requested by NDMA in October 1996. FDA published the OTC pediculicide final monograph in December 1993...
You may also be interested in...
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Perrigo promotes in pricing, planning